Literature DB >> 16935560

Opioid receptor signaling: relevance for gastrointestinal therapy.

Laura M Bohn1, Kirsten M Raehal.   

Abstract

Opiate drugs, such as morphine, are renowned for their analgesic properties. To date, opioid narcotics represent the largest and most potent class of pain relievers available to treat both acute and chronic pain conditions. The use of opiates, however, is severely limited by several adverse side effects. Upon chronic use, opiates can produce tolerance, physical dependence and addiction. Although these conditions warrant consideration, there are acute effects that present more immediate concerns when choosing opiate narcotics for pain therapy. One of the most prevalent side effects, which continues for as long as the opiate is used for pain control, is constipation. This can impact patient compliance, as it is often one of the top reasons why patients discontinue opiate treatment. The challenge, therefore, is to develop pain therapies that preserve potent analgesia while preventing constipation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935560     DOI: 10.1016/j.coph.2006.06.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  20 in total

Review 1.  Functional selectivity of GPCR signaling in animals.

Authors:  Lei Zhou; Laura M Bohn
Journal:  Curr Opin Cell Biol       Date:  2013-12-22       Impact factor: 8.382

Review 2.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 3.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

4.  micro-Opioid receptor stimulation in the medial subnucleus of the tractus solitarius inhibits gastric tone and motility by reducing local GABA activity.

Authors:  Melissa A Herman; Alisa Alayan; Niaz Sahibzada; Barbara Bayer; Joseph Verbalis; Kenneth L Dretchen; Richard A Gillis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-05-20       Impact factor: 4.052

5.  A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.

Authors:  Wei Lei; Rakesh H Vekariya; Subramaniam Ananthan; John M Streicher
Journal:  J Pain       Date:  2019-06-12       Impact factor: 5.820

Review 6.  Current research on opioid receptor function.

Authors:  Yuan Feng; Xiaozhou He; Yilin Yang; Dongman Chao; Lawrence H Lazarus; Ying Xia
Journal:  Curr Drug Targets       Date:  2012-02       Impact factor: 3.465

Review 7.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

Review 8.  β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Handb Exp Pharmacol       Date:  2014

9.  Design, synthesis, and evaluation of biotinylated opioid derivatives as novel probes to study opioid pharmacology.

Authors:  Ya Li; Anna R Chase; Peter F Slivka; Clyde T Baggett; Tina X Zhao; Hang Yin
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

10.  Management of postoperative ileus: focus on alvimopan.

Authors:  Eric L Marderstein; Conor P Delaney
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.